Skip to main content
FinSpry Logo
FinSpry
ENGN logo
ENGN
(NASDAQ)
enGene Therapeutics Inc.
$1.81-- (--)
Loading... - Market loading
OverviewFinancialsForecastStatisticsDividendsHistoricalProfile

enGene Therapeutics Inc. (ENGN) Analyst Forecast

Analyst consensus ratings, 12-month price targets, and expert recommendations for enGene Therapeutics Inc. stock.

Analyst Consensus Rating

Investment consensus from 4 professional research analysts

Consensus Rating

Hold
Based on 4 unique analysts
Low Confidence1.0:1 Buy/Sell

Average Price Target

$3.00
↑ 65.75% Upside

Loading chart...

Strong Sell
Sell
Hold
Buy
Strong Buy

Latest ENGN Analyst Ratings & Recommendations

Recent analyst recommendations with rating changes and price target updates (last 90 days)

Judah Frommer
Morgan Stanley
SellDowngrades
-
Michael Schmidt
Guggenheim
HoldMaintains
-
Andres Y. Maldonado
HC Wainwright
BuyMaintains
$6.00 → $4.00
Yanan Zhu
Wells Fargo
HoldReiterates
$2.00

Frequently Asked Questions

What is the analyst consensus rating for ENGN?

The analyst consensus rating for ENGN is "Hold" based on 4 analyst recommendations.

What is the average price target for ENGN?

The average 12-month price target for ENGN is $3.00, representing an upside of 65.7% from the current price of $1.81.

What do analyst ratings mean?

Analyst ratings indicate investment recommendations: Strong Buy and Buy are bullish signals suggesting the stock may outperform. Hold means the stock is fairly valued. Sell and Strong Sell are bearish signals suggesting potential underperformance. These ratings are based on fundamental analysis and valuation models.

What is a price target?

A price target is an analyst's projection of a stock's fair value over a specific timeframe, typically 12 months. Analysts use fundamental analysis, financial modeling, and industry comparisons to estimate where the stock should trade. Price targets can range from low (conservative) to high (optimistic) estimates.